Hims & Hers Health (HIMS) Falls -10.9% Over 30 Days on FDA Peptide Decision

Key Takeaways

• Hims & Hers Health (HIMS) shares declined approximately 10.9% over the past 30 days, falling from $33.94 on June 26 to $30.24 as of July 27, 2026.
• The sell-off was primarily triggered by the FDA Pharmacy Compounding Advisory Committee's split decision on July 23–24, which recommended six of seven peptides for compounding but rejected emideltide — one of the most commercially anticipated compounds.
• Shares plunged 14% on July 24 alone, the worst single-session decline in nearly six months, breaking through the 50-day moving average.
• Over the broader quarter, HIMS has been flat to slightly positive but experienced extreme volatility, rallying above $38 in early July before giving back gains.
• Analyst consensus remains at Hold, with price targets ranging from $23 to $40, reflecting deep disagreement about the company's peptide and weight-loss growth trajectory.

Hims & Hers Health (HIMS) Company Overview and Market Position

Hims & Hers Health, Inc. is a direct-to-consumer telehealth platform that connects patients with licensed healthcare providers for online consultations, prescriptions, and home delivery of personal care products. Founded in 2017, the company operates under the Hims and Hers brands and has grown to serve nearly 2.6 million subscribers across the United States and select international markets. Its product portfolio spans sexual health, hair loss, skincare, mental health, and weight-loss treatments. The company has increasingly leaned into the GLP-1 weight-loss market and, more recently, peptide-based wellness therapies — a strategic pivot that has attracted both institutional interest and heightened regulatory scrutiny. With a market capitalization of approximately $7 billion, HIMS remains one of the most closely watched names in the consumer telehealth space.

Recent Stock Price Performance for HIMS: Last 30 Days vs. Quarter

Over the last 30 calendar days, HIMS shares declined from a closing price of $33.94 on June 26, 2026, to $30.24 as of the July 27 intraday session — a drop of roughly 10.9%. The bulk of that decline occurred in a single session on July 24, when the stock shed 14% following the FDA advisory committee's mixed peptide ruling. Earlier in the period, the stock had tested levels above $38, meaning the drawdown from the 30-day peak exceeded 20%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Looking at the broader quarter, HIMS closed at $29.39 on April 27 and traded at $30.24 on July 27, representing a modest gain of approximately 2.9%. However, this headline number masks significant intra-quarter turbulence. Shares surged to a multi-month high of $38.28 on July 6, driven by enthusiasm around the oral Wegovy launch and peptide catalyst anticipation, before the late-July regulatory setback erased nearly all of those gains. The quarterly pattern reflects a market that has repeatedly bid up HIMS on growth catalysts, only to reassess when regulatory or execution risks materialize.

What Drove HIMS Stock Price in the Last 30 Days

The dominant catalyst for HIMS over the past 30 days was the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting held on July 23–24, 2026. The committee evaluated seven peptides — including BPC-157, TB-500, KPV, MOTS-C, Epitalon, Semax, and emideltide — for potential inclusion on the 503A Bulk Drug Substances List, which governs which active ingredients licensed compounding pharmacies may legally use. While the panel voted in favor of six of the seven compounds, emideltide was rejected by a narrow 7-6 vote with one abstention. Panel members cited insufficient safety data, manufacturing consistency concerns, and a lack of compelling clinical evidence.

Although the PCAC's recommendation is non-binding, the FDA typically aligns its final decision with advisory committee guidance, and the emideltide rejection renewed doubts about the regulatory path for Hims & Hers' broader peptide strategy. The stock dropped 14% on July 24 in response, crashing through its 50-day moving average. Adding to selling pressure, Bank of America had earlier flagged weaker-than-expected retention rates among new oral Wegovy subscribers, raising concerns about the sustainability of the company's weight-loss revenue ramp. High short interest — reported above 32% of the float — likely amplified the downward move as bearish positioning collided with negative regulatory news.

What Drove HIMS Stock Performance Over the Last Quarter

The quarterly narrative for HIMS has been defined by a tug-of-war between aggressive growth ambitions and mounting execution and regulatory challenges. In mid-April, shares surged from the $19–$21 range to above $31 after the company's oral Wegovy launch with NVO partner Novo Nordisk generated strong initial subscriber numbers. Analysts at Barclays and Canaccord raised price targets to $39 and $40 respectively, citing the branded weight-loss transition as a meaningful revenue driver. The acquisition of Australian telehealth company Eucalyptus for $1.15 billion in mid-2026 further signaled international expansion momentum, adding approximately 850,000 customers and $450 million in annual recurring revenue across eight markets.

However, the optimistic tone was repeatedly tested. Q1 2026 earnings, reported in May, revealed a net loss of $92 million — or $0.40 per share — widely missing the consensus estimate of $0.01 per share profit, even as full-year revenue guidance was raised to $2.8–$3.0 billion. Insider selling by CFO Oluyemi Okupe, who disposed of tens of thousands of shares under a Rule 10b5-1 plan in recent months, added to investor unease. The combination of a disappointing earnings print, persistent GAAP losses, rising debt levels, and the late-July peptide regulatory setback has kept the stock in a wide trading range, with sharp rallies consistently met by equally sharp reversals. From what I see, the AI Trend Prediction Engine can help flag these volatility patterns in advance.

HIMS Stock Forecast Drivers: What Investors Should Watch Next

The near-term outlook for HIMS hinges on several interconnected factors. First, the FDA's final determination on the PCAC peptide recommendations — particularly whether the agency follows through on the six favorable votes — will shape the timeline and scale of the company's peptide revenue opportunity. Leerink Partners has estimated a potential $2.2 billion annual telehealth peptide market, with HIMS positioned to capture roughly 20%, yet meaningful revenue contribution is unlikely before 2028. Second, the company's Q2 2026 earnings report, expected in August, will be scrutinized for subscriber retention metrics on the oral Wegovy program, overall margin trends, and progress toward the raised full-year guidance of $2.8–$3.0 billion in revenue. Third, short interest above 32% creates the potential for sharp short-squeeze rallies on positive catalysts, but also magnifies downside risk during periods of negative sentiment. Finally, macroeconomic conditions affecting consumer discretionary healthcare spending, along with any regulatory developments around GLP-1 compounding, remain important background risks that investors should continue to monitor.

Exploring AI Trading Bots for Volatility Management

As I navigate periods of sharp moves like the one we just saw in HIMS, I often review Tickeron’s AI Trading Bots to see how automated strategies have handled similar setups across different timeframes and risk profiles. It provides a practical way to compare options without replacing my own analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume